Seer researchers find undiscovered links between lung cancer and multiple distinct protein variants via deep, unbiased proteomics analysis

Proteomics is the study and analysis of proteins, including their structures, functions, interactions, and modifications within a biological system. Humans have approximately 20,000 genes that produce over a million different protein variants, including an estimated 100,000 protein isoforms. These protein variants comprise the vast complexity of the proteome that has remained largely unexplored. There is a growing body of literature demonstrating that protein isoforms are of high biomedical importance, because isoforms of a protein that arise from the same gene can have distinct biological functions and play different roles in cellular processes. The study of the proteome at the level of protein variants across populations can inform our understanding of biology and provide future scientific advancements in how we identify and treat disease and manage health.

In a study published on March 29 in the journal PLoS One, Seer scientists collaborating with Luis Diaz, M.D. from the Memorial Sloan Kettering Cancer Center found four structurally distinct protein isoforms that were differentially expressed in non-small cell lung cancer (NSCLC) patients. The identification of protein isoforms that are differentially expressed in NSCLC was made possible by comparing the proteomic profiles of people with cancer versus healthy subjects at peptide-level resolution using deep, unbiased proteomics methods.

“These findings demonstrate that distinct protein isoforms may differentially contribute to diverse biological mechanisms and to the pathogenesis of cancers, potentially paving the road to identify new diagnostic markers or new therapeutic targets,” said Dr. Diaz, Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. “What is especially encouraging here is that these protein isoforms were detected in plasma, a readily accessible sample type, enabling cancer detection and monitoring through liquid biopsy evaluation of patients.”

The study analyzed 188 plasma proteomes from NSCLC patients and healthy controls to identify disease-associated protein isoforms. These protein variants play distinct roles in the body’s biological pathways and can influence disease predisposition and progression. Seer’s deep, unbiased proteomics platform revealed multiple isoforms of proteins, some of which showed significantly different behavior in NSCLC when compared to healthy controls, including bone morphogenetic protein 1 (BMP1), complement component 4a (C4a), complement component 1r (C1r) and lactate dehydrogenase B (LDHB). 

One key isoform of the protein BMP1 had never been previously associated with NSCLC. The researchers found that healthy people had higher levels of a standard long form of the protein, while NSCLC patients had higher levels of a shortened isoform of the protein that lacks the ability to release collagen, which could impact the tumor microenvironment. The findings suggest BMP1 may play a role in NSCLC disease pathogenesis. 

“This study identified novel disease-associated protein isoforms in NSCLC, demonstrating the utility of an unbiased analysis of the proteome at peptide-level resolution, which provides a deeper, more nuanced assessment of the human proteome,” said Asim Siddiqui, Senior Vice President of Research at Seer. “These findings underpin the importance of an unbiased approach to reveal novel biological content such as cancer-specific protein isoforms.”

Future research into the discovered protein isoforms may validate their role in cancer, utility as novel biomarkers, or potential as therapeutic targets for NSCLC. By using a deep, unbiased approach to investigate the proteome at peptide-level resolution, novel protein isoforms that play a biologically significant role can be discovered for a variety of diseases, including cancer, that would otherwise not be discovered using targeted technologies. 

###

About Seer

Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.